'That's Huge, Folks': Amarin's Vascepa Cuts CV Risk By 25% On Top Of Statins
Executive Summary
Cardiovascular outcomes data exceeded expectations for the fish oil pill, vindicating Amarin, which has fought long and hard for Vascepa's place in the CV disease prevention market. A filing based on REDUCE-IT is expected in early 2019.